E1

Energy drinks went mainstream before their cardiac safety evidence did
A preliminary analysis of more than 28,000 FDA adverse-event reports found that reports involving caffeinated energy drinks and stimulant supplements disproportionately included cardiac arrest, myocardial infarction, ventricular arrhythmias, palpitations and other cardiovascular events. Nearly half of stimulant-linked cardiovascular reports involved adults aged 18 to 34.

Cardiometabolic care is screening the pieces. It is not yet connecting them

Cardiometabolic screening is becoming a consumer product. Prevention is still a health-system job

Cardiovascular risk in autoimmune disease begins before the risk calculator notices

Menopause before 40 should not be treated as a reproductive footnote

AstraZeneca’s potential $1.5B insitro deal puts AI on the hardest question in cardiometabolic R&D

The protein boom has a cardiology blind spot

Life insurers are moving from pricing metabolic risk to trying to reduce it

Cardiac arrest is a race against distance. Drones could change the map

As GLP-1 use scales, dermatology is becoming part of obesity care
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
